The King’s College London Gene Therapy Vector Facility (GTVF) is a state-of-the-art facility established to support the scientific community in their delivery of the latest cutting-edge gene therapies into the clinic. With a legacy dating back to 2006, the GTVF is now one of the largest suppliers of GMP-grade viral vectors to clinical trials across Europe, offering:
- Lentiviral vector
- Retroviral vector
- Adeno-associated viral vector (implementation project in-progress)
GTVF at KCL is part of the London Innovation Hub for Gene Therapies (London IHfGT). This is a new UK initiative designed to advance the clinical development of new genetic treatments through the production of GMP (Good Manufacturing Practise) viral vectors.
Why work with the GTVF?
Clients choose to forge long-term partnerships with the KCL GTVF for a number of reasons:
Expertise
Highly skilled team with extensive expertise in vector production, QA/QC and process development
Value
A focus on getting good science through to the clinic and an alignment with early phase development.
Legacy
Over 100 batches of high-quality retro- and lentiviral vectors manufactured for clients in the UK, Europe and USA.
End-to-End
We manage all aspects of viral vector manufacture from sourcing plasmid, project management, production, QC release testing and regulatory support.
Get In Touch
Contact us to discuss your lentiviral vector, retroviral vector, and adeno-associated viral vector GMP manufacturing needs:
Partners
The network of Innovation Hubs for Gene Therapies aims to accelerate academic-led development of novel gene therapies throughout the UK.
Set up in 2021 with £18m of funding from the independent research charity LifeArc, the Medical Research Council (MRC), and the Biotechnology and Biological Sciences Research Council (BBSRC), the hubs will operate as a coordinated network, sharing technical skills and resources.
